Last reviewed · How we verify
Cisplatin + etoposide
Cisplatin and etoposide work together as a chemotherapy combination: cisplatin cross-links DNA to prevent replication, while etoposide inhibits topoisomerase II to block DNA unwinding and repair.
Cisplatin and etoposide work together as a chemotherapy combination: cisplatin cross-links DNA to prevent replication, while etoposide inhibits topoisomerase II to block DNA unwinding and repair. Used for Small cell lung cancer, Non-small cell lung cancer.
At a glance
| Generic name | Cisplatin + etoposide |
|---|---|
| Sponsor | European Lung Cancer Working Party |
| Drug class | Chemotherapy combination (platinum agent + topoisomerase II inhibitor) |
| Target | DNA (cisplatin: alkylating agent); Topoisomerase II (etoposide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that forms covalent bonds with DNA, creating interstrand and intrastrand crosslinks that prevent DNA replication and transcription. Etoposide is a topoisomerase II inhibitor that stabilizes the enzyme-DNA complex, preventing religation of DNA strands and leading to double-strand breaks. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Alopecia
- Mucositis
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (PHASE2)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |